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© 2011 Japanese Society of Tropical Medicine Abstract: Dengue is the most important arboviral disease of humans with over half of the world’s population
living in areas of risk. The frequency and magnitude of epidemic dengue have increased dramatically in the past
40 years as the viruses and the mosquito vectors have both expanded geographically in the tropical regions of the
world. There are many factors that have contributed to this emergence of epidemic dengue, but only three have
been the principal drivers: 1) urbanization, 2) globalization and 3) lack of effective mosquito control. The dengue
viruses have fully adapted to a human-Aedes aegypti-human transmission cycle, in the large urban centers of the
tropics, where crowded human populations live in intimate association with equally large mosquito populations.
This setting provides the ideal home for maintenance of the viruses and the periodic generation of epidemic strains.
These cities all have modern airports through which 10s of millions of passengers pass each year, providing the
ideal mechanism for transportation of viruses to new cities, regions and continents where there is little or no effec-
tive mosquito control. The result is epidemic dengue. This paper discusses this unholy trinity of drivers, along with
disease burden, prevention and control and prospects for the future.
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INTRODUCTION
The last half of the 20
th century has taught us many
lessons about infectious diseases and their resilience in the
face of defeat. The heady victories of the 1950s, 1960s and
1970s over smallpox, malaria, yellow fever, dengue, cholera,
tuberculosis, plague and other major infectious diseases
culminated with the war on infectious diseases being
declared won in 1969! [1] This declaration contributed to
the initation of a period of increasing apathy and compla-
cency in the last three decades of the 20
th century, during
which time the public health infrastructure and hygiene
deteriorated to the point where they provided little protec-
tion against infectious diseases. A new paradigm of
surveillance and emergency response was introduced as the
recommended method of controlling epidemic infectious
diseases. Resources were redirected from infectious diseases
to other noncommunicable public health priorities, and the
Silent Spring era of increased environmental awareness
made it increasingly more difficult to control mosquitoes
and other disease vectors [2–5].
Coincident with this period of apathy, and unrecognized
by public health and infectious disease experts, however,
was the emergence of global trends that would ultimately
drive the re-emergence of many of the diseases that had
been effectively controlled. These trends included un-
precedented population growth, unplanned urbanization
and modern air transport of people, animals and commodities
(globalization), the latter two being driven by economic
growth in the post World War II era [2–6]. The jet airplane
provided the ideal mechanism to transport pathogens to new
geographic regions, and as globalization increased, so too
did the movement of pathogens among urban centers of the
world. Thus, beginning in the 1970s, and accelerating in
the 1980s and 1990s, a global re-emergence of epidemic
infectious diseases occurred and continues as we enter the
second decade of the 21
st century [3, 5]. Dengue fever
provides an ideal case study of how urbanization and
globalization have influenced infectious disease emergence.
HISTORY AND CURRENT STATUS
Prior to World War II, dengue viruses had a global
distribution in the tropics, but because urban populations
were relatively small, and the viruses and mosquito vectors
depended primarily on ocean going vessels for transporta-
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tion among regions, epidemics were sporadic, with long
intervals between them [7]. As a result, most tropical
regions had only one or at most, two viruses circulating at
any one time; dengue fever was not considered a major
public health problem, except when sporadic epidemics
occurred.
It was World War II that planted the seed for the
current dengue pandemic [7]. Dengue fever (DF) and malaria
were two of the major diseases that plagued both the
Japanese and Allied forces in the Pacific and Asian theatres,
with thousands of cases occurring among soldiers [7–9].
The movement of troops and war materials transported the
viruses and the principal mosquito vector, Aedes aegypti, to
most areas of both regions. By the end of the war, many
countries of Asia were hyperendemic with the co-circulation
of all four virus serotypes. The end of the war brought a
surge in economic growth in many Southeast Asian countries
and this was the principal catalyst for the unprecedented
urban growth that began in the 1950s and continues today
(Fig. 1). It was during this period that the first documented
epidemics of dengue hemorrhagic fever (DHF) occurred,
first in the Philippines (1953–1954) and Thailand (1958),
followed in the 1960s by Singapore, Malaysia and Vietnam,
and Indonesia and Burma (Myanmar) in the 1970s [10, 11].
As urbanization and commerce grew, the frequency and
magnitude of epidemic disease continued to increase (Fig. 2).
By the 1980s, DHF had become a leading cause of hospital-
ization and death among children in many countries of
Southeast Asia [11].
After an absence of 25 years, dengue was re-introduced
into the Pacific Islands in 1964 and again in 1971 from the
Americas (DENV-3 and DENV-2, respectively) [12–17].
The DENV-3 was limited to relatively small outbreaks in
Tahiti, but the DENV-2 spread throughout the islands. The
same American genotype of DENV-2 caused severe disease
on some islands and only mild disease on others [14, 17–
19]. Over the next 10 years, all four serotypes were intro-
duced from Asia and caused epidemics in most islands [7].
Epidemic dengue accompanied by severe and fatal hemor-
rhagic disease has been a regular occurrence in the Pacific
islands since that time.
In the Americas, epidemic dengue was effectively
Fig. 1.  Urban growth in Asian and American cities—1950–
2010.
Fig. 2.  Reported dengue/DHF cases in Thailand (A), Indone-
sia (B) and Vietnam (C), by year.5 D.J. Gubler
controlled along with epidemic yellow fever in most of
the region by the Ae aegypti eradication program that
eliminated the mosquito from 23 countries during the 1950s
and 1960s [2, 20]. When this program was terminated in the
early 1970s, Ae aegypti began to reinfest tropical countries
in the region (Fig. 3). This reinvasion by Ae aegypti
coincided with dramatic urban growth in the American
tropics, and by the late 1970s, dengue viruses were begin-
ning to be introduced from Asia [21, 22]. DENV-1 was
introduced in 1977, followed by DENV-2 and -4 in 1981,
and DENV -3 in 1994 [7]. Most likely, multiple strains of
each serotype were introduced, and all four became endemic.
As hyperendemicity developed, epidemic DHF emerged
and currently affects most of the region (Fig. 4) [23].
The dramatic global geographic expansion and the
increased incidence of epidemic dengue coincided exactly
with urban growth and globalization [6]. Currently, an
estimated 3.6 billion people in 124 countries live in areas
of risk for this primarily urban disease [24]. It is not
known how many dengue infections occur each year, but
the estimates range from 50 to over 200 million, many of
these being cases of mild febrile illness that are not reported
as dengue. An estimated 34 million cases of clinical DF, 2
million cases of DHF and over 20,000 deaths occur each
year [24]. In addition to the cases of classical DHF (vascular
leak syndrome), there are many cases of severe dengue
disease that are not reported as dengue because the clinical
presentation is atypical [25–31]. These include patients with
massive hemorrhage and organ failure, neurologic disease,
myocardiopathy and hepatic and renal failure [31]. Dengue
is currently the most important vector-borne virus disease
affecting humans. If the global trends of population growth,
urbanization and globalization continue as projected, we can
expect to see continued increases in the frequency, magnitude
and severity of epidemic dengue. The current global distri-
bution of Ae aegypti, areas at risk and areas with recent
epidemic dengue activity are shown in Fig. 5.
BURDEN OF DISEASE
The actual burden of dengue disease is difficult to
measure because of the low case fatality rate, misdiagnosis,
poor surveillance, and lack of cooperation by the tourism
and other industries [24, 32–35]. Many dengue infections
are misdiagnosed as other tropical diseases such as malaria
[36]. However, dengue is an insidious disease that is always
present in large tropical urban centers, lurking in the shadows
out of sight and out of mind of physicians and public health
officials during interepidemic periods, waiting for the
opportunity to strike, either by mutating to a genetic sub-
Fig. 3.   Reinfestation of tropical America by Aedes aegypti,
1930–2011.
Fig. 4.   The emergence of dengue hemorrhagic fever in the
Americas associated with introduction of new virus
serotypes and the development of hyperendemicity.
Areas with recent dengue transmission
Areas infested with Aedes aegypti Adapted from Gubler, 1998
Fig. 5.   The global distribution of epidemic dengue and the
principal vector mosquito, Aedes aegypti, 2011.6 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
type that has greater epidemic potential and virulence, or by
catching a ride to another city where the population is more
susceptible to that particular serotype. Often times both of
these mechanisms come into play as epidemic strains of
dengue virus spread in infected humans via modern trans-
portation [5, 6, 37].
Epidemics of dengue often cause chaos in the commu-
nities where they occur, resulting in considerable social
upheaval and economic loss, both of which are difficult to
measure; thus the paucity of reliable disease burden data
[38]. Unfortunately, the World Health Organization consis-
tently reports unrealistically low estimates of disease burden
for dengue [39]. Moreover, most dengue endemic countries
have only passive surveillance systems that consistently
underestimate the amount of dengue disease, especially
mild illness, atypical severe disease and deaths [40, 25–30].
Recent studies, however, have tried to more accurately
measure the actual disease burden and cost of dengue [24,
32, 33]. In the Americas, for example, it was estimated that
between 3 to 16 times more cases occurred than were
reported in Colombia, Nicaragua, and Puerto Rico [32]. In
Thailand, Cambodia and Indonesia, however, the underesti-
mates were smaller, only between 3 and 6 times. These are
most likely due to under reporting, however, because Asian
countries routinely fail to report mild dengue or even dengue
fever. This is underscored by a number of cohort and active
surveillance studies in Asia and the Americas showing that
the true incidence of dengue infection was underestimated
by 11 to 250 times [24].
The actual cost of dengue to a community is also
difficult to measure. A recent study in the Americas
estimated that dengue cost the region US$2.1 billion per
year [32]. However, that figure did not include the cost of
vector control, nor did it include any of the costs associated
with loss of tourist dollars, which can be considerable. For
example, epidemic dengue cost an estimated US$90 million
in the state of Gujarat, India in 2007, and US$133 million in
Malaysia and US$127 million in Thailand in 2006 (DS
Shepard, personal communication, 2010). Most of these
dollar estimates grossly underestimate the real cost of the
disease to a community. Even so, the burden of dengue
exceeds many other infectious diseases, including viral
diseases like human papillomavirus and rotavirus [32], and
reaches the same order of magnitude as many other infec-
tious diseases [34].
FACTORS INFLUENCING INCIDENCE 
AND GEOGRAPHIC SPREAD
There are many factors that have influenced the inci-
dence and geographic spread of dengue disease, including
apathy, decay in public health infrastructure, changing life
styles, evolutionary changes in the viruses, and misguided
mosquito control, among others. However, four factors
can be cited as principal drivers of the increased incidence
and spread (Box 1). The failure to control Ae aegypti
mosquitoes in urban environments is closely linked to
changing lifestyles [2]. In the 40 years since 1970, two
things have exacerbated our failure to control the mosquito
vectors: 1) lack of political will and thus resources, and
2) too much emphasis on high technology such as space
spraying of insecticides. The apathy and complacency that
set in after the success of the Ae aegypti eradication program
in the Americas resulted in a redirection of resources away
from successful mosquito control programs, which ultimately
resulted in the deterioration of mosquito control infrastruc-
ture in much of the world. Successful mosquito control
programs were replaced by emergency space spraying of
nonresidual insecticides in response to reported cases of
dengue [2, 41]. This method had high visibility and was
very popular politically, but it simply did not work because
it targeted adult mosquitoes which are normally sequestered
in resting places inside houses where the insecticides do not
reach. In addition, because the passive surveillance relied
on physicians to report cases, the spraying was always too
late and too limited geographically to interrupt transmis-
sion. Changing lifestyles in the past 30 years have also
played an important role in our inability to control dengue.
The global automobile population has exploded during this
time, and used automobile and truck tires provide ideal
oviposition sites and larval habitats for the mosquito vectors.
As a result, they also served as the principal mechanism for
the geographic spread of mosquitoes [42]. In addition, most
consumer goods are packaged in nonbiodegradable plastic
containers, most of which are discarded into the environ-
ment and provide another ideal larval habitat for the
mosquito vectors of dengue [2]. Thus, most of our mosquito
control efforts were focused on controlling adult mosquitoes
using an expensive method that did not work, while our
changing lifestyles were providing an increasing number of
larval habitats for the mosquitoes. The result has been
increased mosquito population densities, increased geo-
graphic spread and increased dengue/epidemics.
Box 1
Major Drivers of the increased Incidence 
and Geographic Spread of Dengue
- Lack of effective mosquito control
- Changing life styles
- Unplanned urbanization
- Globalization7 D.J. Gubler
Two other major drivers of increased incidence and
geographic spread of epidemic dengue were urbanization
and globalization. Aedes aegypti is a highly domesticated
urban mosquito that prefers to live with humans in their
homes, feed on humans and lay eggs in artificial containers
made by humans [7]. Automobile tires and plastic containers
are but two of these types of containers found in the
crowded urban environment and implicated in the high
mosquito population densities. The lack of adequate water
supply in many urban areas makes it necessary to store
water in large containers such as clay jars and cisterns,
another major contribution to increased mosquito densities.
The dramatic urban growth that has occurred in the past 40
years has thus provided the ecological conditions that allow
large populations of Ae aegypti to thrive in intimate associ-
ation with large and crowded human populations in tropical
cities, creating conditions that are ideal for epidemic dengue
transmission.
In Asia, unprecedented urbanization began in the years
following World War II and coincided with a remarkable
economic boom. Cities like Bangkok, Manila, and Jakarta
exploded in population growth, most of it unplanned
(Fig. 1). The result was millions of susceptible people
moving to the cities and living in shanty towns with inade-
quate housing and few or no basic services such as water,
sewer and waste management. The resulting crowded
human communities and large mosquito populations created
ideal conditions for dengue transmission. As noted above,
it was in this setting that epidemic DHF emerged, first
recognized in Manila in 1953–1954, followed by Bangkok
in 1958, although retrospectively, sporadic cases were
identified early in the decade [7, 10]. Epidemics of the
severe disease began to occur in the 1960s and 1970s in
Asia and the Pacific Islands (see above). Incidence and
geographic spread accelerated in the 1980s and 1990s,
with epidemic DF/DHF moving east into Taiwan and
China, south into Australia and west to India, Sri Lanka, the
Maldives, Saudi Arabia and Pakistan [43].
The American region became highly urbanized in the
1970s and today, over 75% of the population live in urban
areas, nearly all of which have been reinfested with Ae
aegypti (Fig. 3) [7, 44, 45]. This re-infestation coincided
with the re-emergence of epidemic dengue beginning in the
1970s and accelerating in the 1980s and 1990s [7, 23].
Since 1977, when only a few countries reported dengue,
most of the region has become hyperendemic with multiple
virus serotypes co-circulating; 28 countries have now
reported the severe forms of dengue disease (Fig. 6).
Globalization has been a direct result of economic
growth. In the past 30 years, globalization has been the
main driver of an integrated global economic system that
includes a transnational flow of knowledge, capital, com-
modities, people and animals. This globalized system has
been closely tied to the increased use of the jet airplane as
the principal mode of transport over the past four decades.
Most large cities in the world have modern airports through
which millions of people pass every year (Fig. 7). Thus,
the global number of passengers traveling by air increased
from an average of 68.5 million per year in the 1950s to
over 2 billion per year in the first decade of the 21
st century
[46]. In 2011, an estimated 2.75 billion people will travel by
airplane, many of them to and from tropical urban centers
where dengue is endemic. The movement of people infected
with dengue viruses has been the principal driver in the
global expansion of this disease. In 2011, the entire tropical
world is hyperendemic with multiple virus serotypes co-
circulating in most large urban centers (Fig. 8). In these
Fig. 6.  Geographic spread of DHF in the Americas, 1981 (A)
and 2011 (B).
Fig. 7.  Mean annual number of global airline passengers by
decade, 1965–2010.8 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
cities, dengue viruses are maintained by low level silent
transmission associated with mild illness during inter-
epidemic periods; periodic epidemics usually occur every 3
to 5 years [7, 43, 47]. These urban centers are the breeding
ground of epidemic dengue, producing viruses with better
resilience and epidemic potential that are then transported
to other cities via infected people traveling by jet airplane
[48–50]. The dengue viruses have fully adapted to humans
and no longer require the sylvatic cycle for survival [37].
They have thus found a perfect environment for survival:
large crowded tropical urban centers where mosquito control
is lacking all of which have modern airports through which
tens of millions of people pass each year.
PREVENTION AND CONTROL
Prevention and control of epidemic dengue has become
increasingly problematic. The disease exists in large
tropical cities where the mosquito vectors live in intimate
contact with the crowded human host. Many of these cities
have populations of 15 to 20 million people. To effectively
control the mosquito vector using current tools, every house
and office in the city must be visited on a weekly basis,
a near impossibility without the help of the community.
Unfortunately, efforts to develop effective community out-
reach programs and ownership have largely failed [51].
Clearly, new tools for mosquito control as well as vaccines
and antiviral drugs are needed to control this disease.
Fortunately, progress is being made on all of these fronts.
For mosquito control, new residual insecticides are on the
horizon and new biological and genetic methods of control
are emerging (Box 2) [52–56]. A discussion of these tools is
beyond the scope of this paper, but it should be noted that no
single tool or method is likely to be effective in controlling
Ae aeqgypti alone. A successful long-term sustainable
control program will require a combination top down-
bottom up approach [2], with the top down component
involving the integration of several new tools and preferably
managed over the longterm by the community [51].
Good progress has also been made in recent years in
the development of antiviral drugs, vaccines and therapeutic
antibodies for dengue viruses [57–62]. It is anticipated that
all may be available within 5 years. The progress with
vaccines has been especially promising, with six tetravalent
candidate vaccines currently in clinical trials, including
three live attenuated candidate vaccines (one in phase III
efficacy trial), one inactivated, one subunit and one DNA
vaccine candidate (Table 1). There are thus great expecta-
tions about the use of vaccines as the principal means of
controlling dengue, but, it must be emphasized that vaccines
are not likely to be a panacea.
A good vaccine for prevention of dengue in endemic
countries must be 1) effective against at least three of the
four serotypes (preferably all 4 and with one dose), 2)
safe, 3) long-lasting (preferably up to 10 years), and 4)
economical. However, lessons learned from yellow fever
show that even if we have such a vaccine for dengue, it may
not be the only answer. There is such a vaccine for yellow
Fig. 8. The global distribution of dengue virus serotypes, 1970 (A) and 2011 (B).
Box 2
New Tools for Control of Aedes aegypti
New residual insecticides
Insecticide treated materials
Biocontrol
Copepods
Wolbachia
Genetic Control
Sterile male release
Genetically resistant mosquitoes9 D.J. Gubler
fever, but it is not used effectively for prevention. In many
yellow fever endemic countries, it is used as an emergency
response tool after an epidemic has been declared. Unfortu-
nately, it is rarely effective when used in this manner because
the response is almost always implemented too late to
impact epidemic transmission.
It should be remembered that there are a number of
other important diseases that can also be transmitted by the
mosquito vectors of dengue (Box 3). Thus, the most effec-
tive prevention and control will be an integrated approach
that combines enhanced mosquito control using the new
tools described above, with vaccines and improved clinical
management including the use of antivirals and therapeutic
antibodies [63].
PROSPECTS FOR THE FUTURE
The global trends discussed above are projected to
continue for the indefinite future. Moreover, it is not anti-
cipated that effective methods of prevention and control
will impact disease incidence and spread in the near term.
Therefore, it is expected that dengue and perhaps other dis-
eases transmitted by Ae aegypti in urban centers of the tropics
will continue to increase in incidence and geographic
spread. To reverse these trends, several things must be done
(Table 2). First, the movement of viruses and vectors via
people traveling by air must be prevented. This problem
has been totally ignored by public health agencies because
of its complex economic and political implications. Second,
vector biologists, epidemiologists, and laboratorians must
be trained and supported to improve capacity in endemic
countries. Third, laboratory-based surveillance must be
developed and implemented in all endemic countries. This
too has been ignored. Fourth, integrated Ae aegypti preven-
tion and control programs must be developed and imple-
mented as regional, not national, programs. Fifth, vaccines,
when they do become available, must be used for preven-
tion as opposed to emergency response. Finally, policy
makers must develop the political will and provide the
support needed to develop, implement and maintain these
programs.
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